Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accounts Payables: 2010-2025

Historic Accounts Payables for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $4.7 million.

  • Anika Therapeutics' Accounts Payables fell 30.46% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year decrease of 30.46%. This contributed to the annual value of $5.6 million for FY2024, which is 9.32% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Accounts Payables is $4.7 million, which was down 0.82% from $4.8 million recorded in Q2 2025.
  • Anika Therapeutics' Accounts Payables' 5-year high stood at $10.0 million during Q1 2024, with a 5-year trough of $4.7 million in Q3 2025.
  • For the 3-year period, Anika Therapeutics' Accounts Payables averaged around $7.1 million, with its median value being $6.8 million (2024).
  • In the last 5 years, Anika Therapeutics' Accounts Payables soared by 31.47% in 2021 and then slumped by 52.26% in 2025.
  • Quarterly analysis of 5 years shows Anika Therapeutics' Accounts Payables stood at $7.6 million in 2021, then increased by 18.88% to $9.1 million in 2022, then tumbled by 31.74% to $6.2 million in 2023, then dropped by 9.32% to $5.6 million in 2024, then tumbled by 30.46% to $4.7 million in 2025.
  • Its Accounts Payables stands at $4.7 million for Q3 2025, versus $4.8 million for Q2 2025 and $5.3 million for Q1 2025.